• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).鉴定 ALK 和 LTK-Ligand 2(增强子-α)的生物活性片段。
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30.
2
Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.增强子α和β(FAM150)是受体酪氨酸激酶ALK和LTK的配体:配体-受体相互作用的层级关系和特异性。
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16.
3
Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.Alk 和 Ltk 配体是受体酪氨酸激酶 Ltk 介导的斑马鱼小眼畸形细胞发育所必需的。
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12027-12032. doi: 10.1073/pnas.1710254114. Epub 2017 Oct 23.
4
ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells.ALK 家族受体酪氨酸激酶在神经嵴和衍生细胞中是体内 ALK 的配体。
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E630-E638. doi: 10.1073/pnas.1719137115. Epub 2018 Jan 9.
5
Structural basis of cytokine-mediated activation of ALK family receptors.细胞因子介导的 ALK 家族受体激活的结构基础。
Nature. 2021 Dec;600(7887):143-147. doi: 10.1038/s41586-021-03959-5. Epub 2021 Oct 13.
6
Multifaceted Roles of ALK Family Receptors and Augmentor Ligands in Health and Disease: A Comprehensive Review.ALK 家族受体及其共刺激配体在健康和疾病中的多效性作用:全面综述。
Biomolecules. 2023 Oct 7;13(10):1490. doi: 10.3390/biom13101490.
7
Comparative Genomics within and across Bilaterians Illuminates the Evolutionary History of ALK and LTK Proto-Oncogene Origination and Diversification.在两侧对称动物中进行比较基因组学研究,揭示了 ALK 和 LTK 原癌基因起源和多样化的进化历史。
Genome Biol Evol. 2021 Jan 7;13(1). doi: 10.1093/gbe/evaa228.
8
A hypothalamic pathway for Augmentor α-controlled body weight regulation.增敏素 α 控制体重调节的下丘脑通路。
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2200476119. doi: 10.1073/pnas.2200476119. Epub 2022 Apr 11.
9
Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.单克隆抗体对间变性淋巴瘤激酶受体酪氨酸激酶的激活与抑制以及多效生长因子激动活性的缺失
J Biol Chem. 2005 Jul 15;280(28):26039-48. doi: 10.1074/jbc.M501972200. Epub 2005 May 10.
10
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.在间变性甲状腺癌患者中鉴定出的间变性淋巴瘤激酶L1198F和G1201E突变并非不依赖配体。
Oncotarget. 2017 Feb 14;8(7):11566-11578. doi: 10.18632/oncotarget.14141.

引用本文的文献

1
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer.核糖核酸酶1驱动的间变性淋巴瘤激酶激活是非小细胞肺癌中的致癌驱动因素和治疗靶点。
Signal Transduct Target Ther. 2025 Apr 18;10(1):124. doi: 10.1038/s41392-025-02206-x.
2
Reanalysis of cryo-EM data reveals ALK-cytokine assemblies with both 2:1 and 2:2 stoichiometries.冷冻电镜数据的重新分析揭示了具有2:1和2:2化学计量比的ALK-细胞因子组装体。
PLoS Biol. 2025 Apr 10;23(4):e3003124. doi: 10.1371/journal.pbio.3003124. eCollection 2025 Apr.
3
Multifaceted Roles of ALK Family Receptors and Augmentor Ligands in Health and Disease: A Comprehensive Review.ALK 家族受体及其共刺激配体在健康和疾病中的多效性作用:全面综述。
Biomolecules. 2023 Oct 7;13(10):1490. doi: 10.3390/biom13101490.
4
A hypothalamic pathway for Augmentor α-controlled body weight regulation.增敏素 α 控制体重调节的下丘脑通路。
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2200476119. doi: 10.1073/pnas.2200476119. Epub 2022 Apr 11.
5
Mechanism for the activation of the anaplastic lymphoma kinase receptor.间变性淋巴瘤激酶受体激活的机制。
Nature. 2021 Dec;600(7887):153-157. doi: 10.1038/s41586-021-04140-8. Epub 2021 Nov 24.
6
Structural basis of cytokine-mediated activation of ALK family receptors.细胞因子介导的 ALK 家族受体激活的结构基础。
Nature. 2021 Dec;600(7887):143-147. doi: 10.1038/s41586-021-03959-5. Epub 2021 Oct 13.
7
gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway.基因沉默通过抑制音猬因子(SHH)信号通路来阻止结直肠癌进展。
J Cancer. 2021 Jan 1;12(1):150-162. doi: 10.7150/jca.46447. eCollection 2021.
8
Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides.靶向癌症中的间变性淋巴瘤激酶(ALK):促凋亡肽的治疗潜力
Cancers (Basel). 2019 Feb 26;11(3):275. doi: 10.3390/cancers11030275.
9
Receptor Tyrosine Kinase-Targeted Cancer Therapy.受体酪氨酸激酶靶向癌症治疗。
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.
10
Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.间变性淋巴瘤激酶(ALK)受体酪氨酸激酶:一个具有多种面孔的催化受体。
Int J Mol Sci. 2018 Nov 2;19(11):3448. doi: 10.3390/ijms19113448.

本文引用的文献

1
Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.β-klotho 结构揭示了内分泌 FGF 信号的“邮政编码”样机制。
Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan 17.
2
ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells.ALK 家族受体酪氨酸激酶在神经嵴和衍生细胞中是体内 ALK 的配体。
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E630-E638. doi: 10.1073/pnas.1719137115. Epub 2018 Jan 9.
3
Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.Alk 和 Ltk 配体是受体酪氨酸激酶 Ltk 介导的斑马鱼小眼畸形细胞发育所必需的。
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12027-12032. doi: 10.1073/pnas.1710254114. Epub 2017 Oct 23.
4
Adopting ALK and LTK.采用间变性淋巴瘤激酶(ALK)和白细胞酪氨酸激酶(LTK)。
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15783-4. doi: 10.1073/pnas.1521923113. Epub 2015 Dec 16.
5
Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.增强子α和β(FAM150)是受体酪氨酸激酶ALK和LTK的配体:配体-受体相互作用的层级关系和特异性。
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16.
6
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.FAM150A和FAM150B是间变性淋巴瘤激酶的激活配体。
Elife. 2015 Sep 29;4:e09811. doi: 10.7554/eLife.09811.
7
The Phyre2 web portal for protein modeling, prediction and analysis.用于蛋白质建模、预测和分析的Phyre2网络门户。
Nat Protoc. 2015 Jun;10(6):845-58. doi: 10.1038/nprot.2015.053. Epub 2015 May 7.
8
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.肝素是孤儿受体酪氨酸激酶ALK的激活配体。
Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916.
9
Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.通过细胞外蛋白质组的信号筛选对人类白细胞酪氨酸激酶(LTK)受体进行去孤儿化。
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15741-5. doi: 10.1073/pnas.1412009111. Epub 2014 Oct 20.
10
A general protocol for the generation of Nanobodies for structural biology.一种用于结构生物学的纳米抗体生成通用方案。
Nat Protoc. 2014 Mar;9(3):674-93. doi: 10.1038/nprot.2014.039. Epub 2014 Feb 27.

鉴定 ALK 和 LTK-Ligand 2(增强子-α)的生物活性片段。

Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

机构信息

Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520;

Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520.

出版信息

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30.

DOI:10.1073/pnas.1807881115
PMID:30061385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6099872/
Abstract

Elucidating the physiological roles and modes of action of the recently discovered ligands (designated ALKAL1,2 or AUG-α,β) of the receptor tyrosine kinases Anaplastic Lymphoma Kinase (ALK) and Leukocyte Tyrosine Kinase (LTK) has been limited by difficulties in producing sufficient amounts of the two ligands and their poor stability. Here we describe procedures for expression and purification of AUG-α and a deletion mutant lacking the N-terminal variable region. Detailed biochemical characterization of AUG-α by mass spectrometry shows that the four conserved cysteines located in the augmentor domain (AD) form two intramolecular disulfide bridges while a fifth, primate-specific cysteine located in the N-terminal variable region mediates dimerization through formation of a disulfide bridge between two AUG-α molecules. In contrast to AUG-α, the capacity of AUG-α AD to undergo dimerization is strongly compromised. However, full-length AUG-α and the AUG-α AD deletion mutant stimulate similar tyrosine phosphorylation of cells expressing either ALK or LTK. Both AUG-α and AUG-α AD also stimulate a similar profile of MAP kinase response in L6 cells and colony formation in soft agar by autocrine stimulation of NIH 3T3 cells expressing ALK. Moreover, both AUG-α and AUG-α AD stimulate neuronal differentiation of human neuroblastoma NB1 and PC12 cells in a similar dose-dependent manner. Taken together, these experiments show that deletion of the N-terminal variable region minimally affects the activity of AUG-α toward LTK or ALK stimulation in cultured cells. Reduced dimerization might be compensated by high local concentration of AUG-α AD bound to ALK at the cell membrane and by potential ligand-induced receptor-receptor interactions.

摘要

阐明受体酪氨酸激酶间变性淋巴瘤激酶(ALK)和白细胞酪氨酸激酶(LTK)的最近发现的配体(命名为 ALKAL1、2 或 AUG-α、β)的生理作用和作用模式受到生产足够数量的两种配体及其稳定性差的限制。在这里,我们描述了 AUG-α 和缺失 N 端可变区的缺失突变体的表达和纯化程序。通过质谱对 AUG-α 的详细生化特性进行分析表明,位于增强子结构域(AD)中的四个保守半胱氨酸形成两个分子内二硫键,而位于 N 端可变区的第五个、灵长类特异性半胱氨酸通过形成二硫键介导两个 AUG-α 分子的二聚化。与 AUG-α 相反,AUG-α AD 发生二聚化的能力受到严重损害。然而,全长 AUG-α 和 AUG-α AD 缺失突变体均能刺激表达 ALK 或 LTK 的细胞发生类似的酪氨酸磷酸化。AUG-α 和 AUG-α AD 均可刺激 L6 细胞中的 MAP 激酶反应和 NIH 3T3 细胞中通过自分泌刺激表达 ALK 的细胞形成软琼脂集落的类似特征。此外,AUG-α 和 AUG-α AD 均可以类似的剂量依赖性方式刺激人神经母细胞瘤 NB1 和 PC12 细胞的神经元分化。总之,这些实验表明,缺失 N 端可变区对 AUG-α 在培养细胞中对 LTK 或 ALK 刺激的活性的影响最小。二聚化的减少可能通过与细胞膜上 ALK 结合的高浓度 AUG-α AD 得到补偿,也可能通过潜在的配体诱导的受体-受体相互作用得到补偿。